CO

Cooper Companies IncNASDAQ COO Stock Report

Last reporting period 31 Jul, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

21.877

Large

Exchange

XNAS - Nasdaq

COO Stock Analysis

CO

Neutral

Based on Eyestock quantitative analysis, COO`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

57/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-27.4 %

Overvalued

Market cap $B

21.877

Dividend yield

0.02 %

Shares outstanding

49.456 B

The Cooper Cos, Inc. operates as a medical device company. The company is headquartered in San Ramon, California and currently employs 14,000 full-time employees. The firm operates through two segments: CooperVision and CooperSurgical. CooperVision segment is engaged in developing, manufacturing and marketing a range of products for contact lens wearers, featuring advanced materials and optics. CooperVision segment designs its products to solve vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigue, with a broad collection of spherical, toric and multifocal contact lenses. CooperSurgical segment focus on advancing the health of women, babies and families through a diversified portfolio of products and services focusing on women's health and fertility. CooperSurgical segment supplies the family health care market with a diversified portfolio of products and services. Its office and surgical offerings include products that facilitate surgical and non-surgical procedures that are commonly performed primarily by obstetricians and gynecologists.

View Section: Eyestock Rating